Valuation: H. Lundbeck A/S

Capitalization 41.24B 6.49B 5.52B 5.17B 4.85B 8.94B 589B 9.77B 60.22B 23.28B 277B 24.36B 23.85B 1,008B P/E ratio 2025 *
11x
P/E ratio 2026 * 9.81x
Enterprise value 49.92B 7.86B 6.68B 6.25B 5.87B 10.82B 713B 11.82B 72.9B 28.18B 336B 29.49B 28.87B 1,220B EV / Sales 2025 *
2.04x
EV / Sales 2026 * 1.82x
Free-Float
30.74%
Yield 2025 *
2.9%
Yield 2026 * 3.19%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.02%
1 week-1.19%
Current month-2.66%
1 month-4.80%
3 months+0.05%
6 months+12.43%
Current year+4.65%
More quotes
1 week 42.74
Extreme 42.74
44.26
1 month 42.56
Extreme 42.56
45.66
Current year 27.2
Extreme 27.2
47.78
1 year 27.2
Extreme 27.2
47.78
3 years 25.12
Extreme 25.115
49.38
5 years 23.3
Extreme 23.295
49.38
10 years 23.3
Extreme 23.295
49.38
More quotes
Manager TitleAgeSince
Chief Executive Officer 58 2023-09-30
Director of Finance/CFO 48 2022-08-31
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 66 2015-03-24
Director/Board Member 66 2015-03-24
Director/Board Member 59 2018-03-19
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.02%-1.19%+3.99%+63.85% 6.49B
+1.13%+3.14%+42.82%+123.47% 102B
+0.90%+0.54%+69.31%+154.50% 47.51B
+1.72%+3.86% - - 22.25B
-3.40%-5.83%+8.92%-9.92% 9.94B
-0.50%+0.22%-17.39%-5.92% 8.51B
-2.05%-2.45%-11.74%-5.33% 8B
-0.08%+2.07%+26.16%+25.32% 5.88B
-0.52%+1.84%+13.40%+58.02% 3.67B
+0.98%-0.19%-6.22%-2.30% 3.63B
Average -0.18%+0.61%+14.36%+44.63% 21.75B
Weighted average by Cap. +0.66%+1.84%+39.43%+104.80%
See all sector performances

Financials

2025 *2026 *
Net sales 24.53B 3.86B 3.28B 3.07B 2.89B 5.32B 350B 5.81B 35.82B 13.84B 165B 14.49B 14.18B 599B 25.18B 3.96B 3.37B 3.15B 2.96B 5.46B 359B 5.96B 36.76B 14.21B 169B 14.87B 14.56B 615B
Net income 3.89B 613M 521M 487M 458M 843M 55.57B 922M 5.68B 2.2B 26.16B 2.3B 2.25B 95.13B 4.36B 687M 584M 547M 513M 946M 62.32B 1.03B 6.37B 2.46B 29.33B 2.58B 2.52B 107B
Net Debt 8.68B 1.37B 1.16B 1.09B 1.02B 1.88B 124B 2.06B 12.68B 4.9B 58.35B 5.13B 5.02B 212B 4.47B 704M 599M 560M 526M 969M 63.86B 1.06B 6.53B 2.52B 30.06B 2.64B 2.59B 109B
More financial data * Estimated data
Logo H. Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,700
More about the company
Date Price Change Volume
25-12-16 43.24 kr 0.00% 43,601
25-12-15 43.24 kr -0.28% 449,898
25-12-12 43.36 kr -0.18% 269,415
25-12-11 43.44 kr -1.27% 438,628
25-12-10 44.00 kr +0.55% 356,112

Delayed Quote Nasdaq Copenhagen, December 16, 2025 at 07:21 am EST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
43.24DKK
Average target price
48.59DKK
Spread / Average Target
+12.37%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. HLUN B Stock